Kornimate/medical-research-clean huggingface dataset:
melanin recurrence in scalpel and laser gingival depigmentation in thin and thick phenotypes.

Conditions: Melanin Hyperpigmentation

Summary: this study aimed to compare melanin pigmentation recurrence, pain perception and wound healing between laser and scalpel surgeries in thin and thick gingival phenotypes.thirty patients (60 sites) were included in this study. they had bilateral physiologic melanin hyperpigmentation in the upper anterior segment with severe grade ii melanin hyperpigmentation. the patients were divided into two groups: each with fifteen patients with severe grade ii melanin pigmentation, one with thin gingiva and another with thick gingiva. melanin depigmentation was done in one side using scalpel no. 15 and other side with diode laser.

background: removal of unsightly pigmented gingiva is the need for a pleasant and confident smile. many studies were done to study the melanin recurrence in both surgical and laser melanin depigmentation. to best of our knowledge, there is no published article regarding comparison of melanin recurrence between both techniques taking in consideration the gingival phenotype. so this study aimed to compare melanin pigmentation recurrence, pain perception and wound healing between laser and scalpel surgeries in thin and thick gingival phenotypes. methods: thirty patients (60 sites) were included in this study. they had bilateral physiologic melanin hyperpigmentation in the upper anterior segment with severe grade ii melanin hyperpigmentation. the patients were divided into two groups: each with fifteen patients with severe grade ii melanin pigmentation, one with thin gingiva and another with thick gingiva. melanin depigmentation was done in one side using scalpel no. 15 and other side with diode laser.

Eligibility criteria:
inclusion criteria: (i) be aged at least 20 years, (ii) had bilateral physiologic melanin hyperpigmentation of gingiva (dark gums) in the anterior segment with severe grade ii melanin hyperpigmentation (according to modification of melanin index categories 1977), (iii) periodontally healthy with good oral hygiene, (iv) had esthetic concern, (v) systemically healthy, (vi) no dental crowding and (vii) those willing to undergo minor surgical procedures. exclusion criteria: (i) any systemic disease associated with pathological hyperpigmentation), (ii) non-treated periodontal disease, (iii) chronic smokers, (iv) subjects with a mouth breathing habit (ii) subjects with crown restorations or fillings involving the incisal edge on anterior maxillary teeth, (v) non-compliant patients (vi) missing any of the six maxillary anterior teeth and having millers class iii or class iv recession (vii) pregnant or lactating females and (viii) (ix) gingival pigmentation of hemoglobin, melanoid, melanoma and carotene , (x) gingival pigmentation adjacent to amalgam restoration, and (xi) long-term usage of antimalarial drugs and minocycline.

Keywords: depigmentation; healing; laser; melanin; pain; phenotype
effect of a fibrate and a statin on endothelial dysfunction

Conditions: Diabetes Mellitus; Metabolic Syndrome

Summary: the study will compare the effect of atorvastatin to the effect of fenofibrate on endothelial function in patients with diabetes mellitus or the metabolic syndrome.

the study will compare the effect of atorvastatin to the effect of fenofibrate on endothelial function in patients with diabetes mellitus or the metabolic syndrome. the study is a double blind, placebo controlled, crossover study with the order of treatment randomized. patients will receive each treatment for 8 weeks with a 1 week rest period between treatment periods. endothelial function will be tested using non-invasive techniques before and after each treatments. a total of 40 subjects with diabetes or the metabolic syndrome will be enrolled at boston medical center.

Eligibility criteria:
inclusion criteria: * age greater than 30 years * adult-onset dm (defined as fasting glucose greater than 125 mg/dl or by ongoing treatment with an oral hypoglycemic agent) or metabolic syndrome (defined as at least 3 of the following: 1. hdl less than 40 mg/dl for men or less than 50 mg/dl for women; 2. triglycerides greater than 150 mg/dl; 3. waist circumference greater than 40 inches for men and greater than 35 inches for women; 4. fasting glucose greater than 100 mg/dl). * ldl cholesterol level less than 140 mg/dl * able to provide informed consent and complete study procedures exclusion criteria: * change in therapy for glucose control or blood pressure less than 1 month before entry * hemoglobin a1c greater than 8.0%. * renal insufficiency (serum creatinine greater than 1.6 mg/dl in men or 1.5 mg/dl in women. * any investigational drug less than 1 month before entry. * pregnancy (excluded by urine pregnancy test at study entry with ongoing use of reliable form of birth control) or lactation * liver function tests or serum creatinine kinase (ck) greater than 3 times upper limit of normal. * clinically evident major illnesses or other problem that would make participation inappropriate * clinical history of symptomatic cholelithiasis * patients with coronary artery disease, peripheral arterial disease, or cerebral vascular disease will not be enrolled if they are currently taking lipid-lowering therapy * patients taking more than 40 mg/day of atorvastatin will be excluded. there is no "ceiling" level for patients taking fibrates.

Keywords: endothelium obesity diabetes mellitus dyslipidemia
efficacy and tolerability of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients

Conditions: Breast Cancer Patients in Premenopausal; Estrogen and/or Progesterone Receptor Positive

Summary: in premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. in this trial, we sought to compare the efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable,estrogen and/or progesterone receptor positive breast cancer patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of breast cancer * received standard treatment (chemotherapy, operation, or radiotherapy) * premenopausal * estrogen and/or progesterone receptor positive exclusion criteria: * metastatic tumors * during pregnancy or lactation
sleep, circadian rhythm & skin health

Conditions: Healthy; Psoriasis; Eczema; Acne

Summary: the purpose of this study is to explore the mechanisms behind how sleep quality may affect skin aging, skin integrity and skin disease.


Eligibility criteria:
inclusion criteria: * males or females ages 18 years and above * capable of giving informed consent * adults who are either healthy, normal volunteers or those with a skin disease including but not limited to eczema, psoriasis, acne or other inflammatory dermatoses * fitzpatrick skin type i-vi * in good general health * willing to cooperate with study instructions exclusion criteria: * volunteers 18 years or younger * any serious medical or physical condition that would cause the subject significant discomfort with study procedures * women who are pregnant, nursing, or who may become pregnant in the next 3 months

Keywords: sleep skin circadian rhythm
effects of sleep quality on melatonin levels and inflammatory response after major abdominal surgery

Conditions: Sleep Deprivation

Summary: endogenous melatonin is produced by the pineal gland at night under normal conditions and regulates the sleep-wake cycle. artificial light administered at night suppresses melatonin production and sleep disturbances are accompanied by abnormal melatonin secretion such as phase delay. therefore, dramatic disturbances of endogenous rhythms in intensive care unit patients have remarkable effects on melatonin production. in addition to its physiological roles in regulating sleep patterns, melatonin has been demonstrated to provide antiinflammatory effects in experimental models. although some previous studies have investigated the circadian pattern of melatonin in intensive care unit patients, the investigators think that the present study is the first one that will assess the effects of controlling noise and light on melatonin and inflammatory response after major abdominal surgery.

this study is going to be conducted in accordance with the helsinki declaration and has been approved by eskisehir osmangazi university ethics committee. forty consecutive patients, aged 18-65, who will undergo elective major abdominal operations will be enrolled in the study after obtaining informed consent. all patients will receive adequate postoperative pain management with the pain buster ® system and patient-controlled intravenous analgesia (pca). the patients will be randomly assigned to either the experimental group or the control group. the control group will receive the usual care. the patients in the experimental group will be screened in the side-rooms where normally the patients who either have infections or are at risk of infection, are nursed. the study intervention will include dimming the lights to 40 lux and closing the doors of the side-room to decrease the noise level below 40 decibels (db) between 11:00 p.m.-5:00 a.m.

Eligibility criteria:
inclusion criteria: * patients undergoing elective major abdominal surgery exclusion criteria: * any evidence of inflammatory diseases during the postoperative care (e.g. anastomotic leakage)
effect of i-shape incısıon technique on inter-implant papilla: a prospective randomized clinical trial

Conditions: Tooth Loss; Bone Loss

Summary: regenerating a predictable inter-implant papilla is the most complex and challenging aspect of implant dentistry. the aim of the study was to compare the efficacy of i shaped incision technique and conventional midcrestal incision technique for interimplant papilla reconstruction in a 6 month clinical trial.

a total of 40 implants were placed in 12 patients. groups were determined at second stage surgery, i shape technique used in test group and mid-crestal technique used in control group. the clinical parameters, including modified plaque index, modified sulcus bleeding index, probing depth, keratinized tissue level were recorded baseline, 3 and 6 month. the vertical distance between the crests top-contact point was evaluated with digital periapical radiographs at baseline 3 and 6 month. also the clinical photographs were taken baseline, 3 and 6 month. two t shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images. with these images the ratio of the papilla area in proportion to the embrasure area and the papilla classification was measured. non-parametric test were used for statistically analysis.

Eligibility criteria:
inclusion criteria: * no sistemic condition, and age \> 18 years, * healthy soft tissue (bleeding on probing (bop) ≤ 20%, plaque index ≤ 15%, * in a need of at least two collateral implants in the maxilla from second premolar to second premolar * sufficient keratinized tissue * no bone augmentation procedures before implant placement * use of tobacco 10n ≥ cigarettes daily * sufficient distance between opposite occluding dentition at the proposed implant sites exclusion criteria: * history of aggressive periodontitis, * systemic diseases such as diabetes * pregnant or lactating women * radiation therapy in the head and neck area wihtin the previous 12 months, * heavy smokers * bruxism.

Keywords: esthetic inter-implant papilla soft tissue tickness crestal bone loss second stage surgery
clinical application of cholangiojejunostomy in the surgical treatment of cholelithiasis with moderate dilatation of common bile duct

Conditions: Cholangiojejunostomy; Cholelithiasis

Summary: this study evaluates the clinical application of cholangiojejunostomy in the surgical treatment of cholelithiasis with moderate dilatation of common bile duct. half of participants will receive hepatectomy, cholangiojejunostomy and t-tube drainage, while the other half will receive hepatectomy and t-tube drainage.


Eligibility criteria:
inclusion criteria: * hepatic bile duct stone disease, need surgery * no residual stones in the operation * extrahepatic bile duct dilatation, 15-30 mm in diam. * no relaxation or stenosis of the sphincter of oddi exclusion criteria: * patient involuntary * surgical treatment can not be performed because of various reasons. * intrahepatic and extrahepatic bile duct stones can not be taken away * with other biliary tract diseases, such as bile duct cancer * oddi sphincter relaxation or stenosis * loss to follow-up

Keywords: moderate dilatation of common bile duct
hidden slow conduction ablation for recurrent atrial fibrillation: unmasking the arrhythmogenic substrate (unmask-af)

Conditions: Atrial Fibrillation

Summary: over recent years, pulmonary vein isolation (pvi) procedures have demonstrated progressively enhanced efficacy and safety, resulting in a substantial increase in the number of atrial fibrillation ablations, not only as a first-line treatment but also for repeat procedures. however, there is still a notable lack of randomized evidence in this area, which limits guidance and decision-making in clinical practice. recently, the investigators found that employing short-coupled atrial extrastimuli revealed highly fragmented or double atrial evoked electrograms (egms) in af patients, termed as hidden slow conduction (hsc). identifying hsc sites may provide insight into the early identification of the arrhythmogenic substrate, offering a potential target for ablation this multi-center, prospective, randomized, controlled trial will include two arms: one investigational (pv reconnection + hsc) and one control (pv reconnection). all the subjects will be followed for 12 months after the ablation procedure. the aim of our study is to investigate the impact of ablating hsc sites on arrhythmia recurrence in repeat ablation procedures. the hypothesis is that the additional ablation of hsc zones may improve the freedom from atrial arrhythmia recurrence after repeat ablation procedure.


Eligibility criteria:
inclusion criteria: * recurrent paroxysmal af (continuous af episode lasting longer than 30 s but terminating spontaneously or with intervention within 7 days of onset), recurrent persistent af (continuous af episode lasting longer than 7 days but \< 1 year) and recurrent long standing persistent af (continuous af ≥1 year in duration, in patients where rhythm control management is being pursued) * previous pvi procedure * age \> 40 years * willing and capable of providing consent * able and willing to comply with all follow-up testing and requirements exclusion criteria: * additional left atrial ablations during the previous procedures (es. posterior wall isolation, anterior line, roof line, cfae and others) * acute illness, active systemic infection, or sepsis * presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation. * severe mitral regurgitation * women who are pregnant, lactating, or who are planning to become pregnant during the course of the clinical investigation

Keywords: catheter ablation re-do procedures hidden slow conduction functional substrate ablation
efficacy of quetiapine in generalised social anxiety disorder

Conditions: Social Anxiety Disorder

Summary: this trial will explore the efficacy of quetiapine in social anxiety disorder, generalized type. the following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with the lsas


Eligibility criteria:
inclusion criteria: * written confirmed consent, * all patients meet the dsm iv criteria for generalized social anxiety disorder, * a score ≥ 60 on the lsas, * male and female aged between 18 and 65 years exclusion criteria: * presence of any primary axis i diagnosis other than social anxiety disorder according to dsm-iv, * alcohol and/or substance abuse according to dsm-iv criteria within the last 12 months, * any personality disorder as the primary diagnosis, with the exception of avoidant personality disorder, * patients at risk of suicide

Keywords: patients with sad
effect of dietary flavonoids on intestinal microbiota, intestinal inflammation and metabolic syndrome

Conditions: Metabolic Syndrome X; Inflammation

Summary: the investigators have hypothesized that dietary flavonoids reduce insulin resistance and subclinical inflammation secondary to reductions in intestinal inflammation and permeability and that these events are mediated through alterations in gut microbiota composition. to test this hypothesis, 30 overweight/obese men and women will be provided two well-controlled diets that are identical in macronutrient content (protein, 17% en; fat, 30% en; carbohydrate, 53% en), but differ markedly in flavonoid content (low flavonoid diet, 10 mg/1000 kcals; high flavonoid diet, 340 mg/1000 kcals). all meals for both diets will be prepared and fed for 6 weeks each in a randomized cross-over design with endpoints determined in duplicate during the last week of each diet period.


Eligibility criteria:
inclusion criteria: * bmi between 25 and 35 kg/m2 exclusion criteria: * documented presence of atherosclerotic disease; * diabetes mellitus * uncontrolled hypertension * renal, hepatic, endocrine, gastrointestinal or other systemic disease * for women, pregnancy, breast feeding or postpartum \< 6 months * history of drug or alcohol abuse * history of depression or mental illness requiring hospitalization within the last 12 months * use of antibiotics within the last 6 months * multiple food allergies or significant food preferences or restrictions that would interfere with diet adherence * chronic use of over-the-counter medication which would interfere with study endpoints including nsaids, laxatives and antacids * lifestyle or schedule incompatible with the study protocol * other medical, psychiatric, or behavioral conditions that in the view of the principal investigator may present a safety hazard to the participant or interfere with study participation or the ability to follow the intervention protocol.

Keywords: flavonoids insulin resistance plasma lipids intestinal microbiome intestinal inflammation subclinical inflammation
proactive treatment of tacrolimus ointment for adult facial seborrheic dermatitis

Conditions: Seborrheic Dermatitis

Summary: the purpose of this study is to determine whether proactive use of 0.1% tacrolimus ointment once or twice weekly can keep adult facial sd in remission and reduce the incidence of exacerbation.

seborrhoeic dermatitis (sd) is a common chronic papulosquamous dermatosis, affecting 2% to 10% of the adult population, mainly those between the ages of 20 and 50 years with a male bias. the affected skin appears erythematous and oedematous, covered with yellow-brown scales, and is often accompanied by pruritus. it typically affects areas containing sebaceous glands, particularly the scalp, ears, face, chest, and intertriginous areas. sd has a chronic course, and relapse is common. therefore, therapy is directed toward reducing the symptoms or aggravating factors of sd, such as loosening and removal of scales and crusts, inhibition of yeast colonization, control of secondary infection, and reduction of erythema and pruritus. standard topical treatments for sd include corticosteroids and anti-mycotic medications. however, the chronic use of topical corticosteroids particularly on the face could result in undesirable outcomes, such as telangiectasia, atrophy, striae, peri-oral dermatitis, or tachyphylaxis, and early relapse after discontinuation of treatment. sd relapse prevention strategies have not yet been established, so the investigators suspected that intermittent use of tacrolimus ointment can be effective in preventing sd relapse.

Eligibility criteria:
inclusion criteria: * at least 18 years of age with a diagnosis of facial seborrhoeic dermatitis exclusion criteria: * taking other systemic or topical treatments for facial seborrhoeic dermatitis within the previous 4 weeks * a known allergy to the components of tacrolimus ointment * malignant neoplasm; immunologic abnormality * active infection * other definitive cutaneous findings such as erythroderma, acne, and psoriasis

Keywords: facial seborrhoeic dermatitis, tacrolimus
characterizing breast cancer with 18f-fes pet/ct

Conditions: Breast Cancer

Summary: 18f-fluoroestradiol (fes) is radioactive labeled estradiol, developed for in vivo visualization of estrogen receptor (er) using positron emission tomography (pet). in this prospective study, 18f-fes pet/ct will be used to evaluate er activity of metastatic disease and their potential sensitivity to endocrine therapy in er-positive breast cancer.


Eligibility criteria:
inclusion criteria: * suspected or confirmed metastatic er-positive breast cancer; * 18f-fdg pet/ct within two weeks; * signed written consent. exclusion criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
treatment of schizophrenic patients with ziprasidone

Conditions: Schizophrenia

Summary: to determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic greek patients.

sampling method details: non-interventional study (subjects chosen by physician in accordance to their usual practice).

Eligibility criteria:
inclusion criteria: * usual clinical practice of physician exclusion criteria: * none

Keywords: ziprasidone in patients with schizophrenia
anticholinergics for cervical edema in labor

Conditions: Labor Dystocia

Summary: the purpose of this study is to is to determine the clinical effectiveness of a single dose of intravenous (iv) medication for the prevention of labor arrest and cesarean delivery in primiparous women undergoing trial of labor.


Eligibility criteria:
inclusion criteria: * primiparous * viable single intrauterine pregnancy -≥ 34 weeks of gestation * ruptured membranes * category i tracing at time of inclusion * active phase of labor (\>=6 cm of cervix dilation) exclusion criteria: * category ii or iii tracing * allergy to the study medication (iv diphenhydramine)

Keywords: dilation labor